Nanomedicine activation profile determines efficacy depending on tumor c-Myc expression

The Innovation Center of NanoMedicine reported in ACS Nano together with the group of Prof. Yu Matsumoto of Otorhinolaryngology and Head and Neck Surgery and the group of Prof. Horacio Cabral of the Department of Bioengineering in the University of Tokyo that the efficacy of polymeric nano-micelles with different drug activation profile depends on the expression level of c-Myc, one of the major proto-oncogenes, has been developed. Continue reading at Physorg